Amarin Corp Plcuk (AMRN) Cash from Investing Activities (2010 - 2026)

Amarin Corp Plcuk (AMRN) reported Cash from Investing Activities of -$8.3 million for Q1 2026, down 168.78% year-over-year from $12.1 million in Q1 2025, and down 136.01% quarter-over-quarter from -$3.5 million in Q4 2025.

Amarin Corp Plcuk (AMRN) Cash from Investing Activities (2010 - 2026) Analysis & Trends

Amarin Corp Plcuk (AMRN) has 16 years of Cash from Investing Activities data on file, last reported at -$8.3 million in Q1 2026.

  • Cash from Investing Activities for Q1 2026 came in at -$8.3 million, down 168.78% year-over-year; the trailing twelve-month figure through Mar 2026 was -$11.5 million (up 81.59% YoY), and the FY2025 annual result was $8.8 million, up 119.2% from the prior year.
  • Cash from Investing Activities declined to -$8.3 million in Q1 2026 per AMRN's latest filing, from -$3.5 million in the prior quarter.
  • Over five years, Cash from Investing Activities peaked at $99.0 million in Q1 2022 and troughed at -$71.0 million in Q4 2023.
  • A 5-year average of $6.1 million and a median of $4.7 million in 2024 frame the typical range for Cash from Investing Activities.
  • On a YoY basis, Cash from Investing Activities climbed as much as 246.45% in 2024 and fell as far as 283.8% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at -$27.8 million in 2022, then tumbled by 155.22% to -$71.0 million in 2023, then jumped by 67.83% to -$22.8 million in 2024, then soared by 84.61% to -$3.5 million in 2025, then plunged by 136.01% to -$8.3 million in 2026.
  • Business Quant data shows AMRN's Cash from Investing Activities at -$8.3 million in Q1 2026, -$3.5 million in Q4 2025, and -$12.1 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn -1.98 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn -3.92 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn -1.04 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn -574.00 Mn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn -10.21 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn -716.00 Mn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 1.77 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn 785.00 Mn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn -131.00 Mn
10 Amarin Corp Plcuk 5.84 Bn 5.66 Bn 17.77 Mn -8.30 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -8.30 Mn
Mar 31, 2026 -8.30 Mn
Dec 31, 2025 -3.52 Mn
Dec 31, 2025 -3.52 Mn
Sep 30, 2025 -12.13 Mn
Sep 30, 2025 -12.13 Mn
Jun 30, 2025 12.41 Mn
Jun 30, 2025 12.41 Mn
Mar 31, 2025 12.06 Mn
Mar 31, 2025 12.06 Mn
Dec 31, 2024 -22.84 Mn
Dec 31, 2024 -22.84 Mn
Sep 30, 2024 -56.55 Mn
Sep 30, 2024 -56.55 Mn
Jun 30, 2024 4.70 Mn
Jun 30, 2024 4.70 Mn
Mar 31, 2024 28.72 Mn
Mar 31, 2024 28.72 Mn
Dec 31, 2023 -71.00 Mn
Dec 31, 2023 -71.00 Mn